Results 271 to 280 of about 263,847 (351)
ABSTRACT Alnus glutinosa is one of only three lineages within the order Fagales capable of establishing root nodule symbiosis (RNS). Although a fragmented genome assembly of A. glutinosa was previously available, its limited quality, combined with the lack of comprehensive transcriptomic resources, has constrained in‐depth comparative and functional ...
Zijian Liu +11 more
wiley +1 more source
PlatROB: An open-source, modular, and low-cost hardware platform for mobile robotics and AI education. [PDF]
Balbuena J +4 more
europepmc +1 more source
An Optimized Parameterization of Sub‐Grid Scale Advection for Convection Permitting Models
Abstract Convection‐permitting models (CPMs) explicitly resolve deep convection yet under‐resolve the organized lateral exchanges among drafts and their environment that control entrainment/detrainment, precipitation efficiency, and mesoscale structure.
Samson Hagos +3 more
wiley +1 more source
Abstract High‐resolution climate simulations are essential to study sub‐daily extreme precipitation, yet their computational demands make long‐term large‐ensemble simulations over a large geographical region often infeasible. We introduce a case‐selective dynamical downscaling (CSDD) framework that reconstructs extreme precipitation statistics at ...
Wout Dewettinck +4 more
wiley +1 more source
Reliable Biomarkers of Descending Pain Inhibition: A Laser-Evoked Potential and Behavioural Study. [PDF]
Wang D +8 more
europepmc +1 more source
Results of the Childhood Cancer and Leukaemia Group's United Kingdom Relapsed Wilms Tumour Trial
ABSTRACT Background The United Kingdom relapsed Wilms tumour (UKW‐R) trial aimed to improve the historically low survival rates after relapse of Wilms tumour (WT) through a prospective national risk‐stratified protocol. The trial also evaluated efficacy and toxicity of high‐dose melphalan.
Sucheta J. Vaidya +10 more
wiley +1 more source
ABSTRACT Purpose Chemoimmunotherapy with irinotecan, temozolomide, and dinutuximab (I/T/DIN) has emerged as first‐line therapy for relapsed/refractory (r/r) high‐risk neuroblastoma (HRNB) in North America. Topotecan and cyclophosphamide (T/C) are often used in combination with dinutuximab in the setting of lack of response, progression, or incomplete ...
Benjamin J. Lerman +17 more
wiley +1 more source
Measuring deiodinase activity: a need for standardization? [PDF]
Wiersema J +10 more
europepmc +1 more source

